ALLO-501,allo-501A
allogene therapeutics
['lymphoma']
while at #asco23, moffitt s joined us at the moffitt booth to discuss phase 1 results with anti-cd19 allogeneic car t allo-501/501a in relapsed/refractory large b-cell lymphoma (r/r lbcl). #moffittasco23 
Moffitt Cancer Center is a global leader in patient care, research and education with a mission to contribute to the prevention and cure of cancer.